Evidence map›Paper›PMID 39297970›Full record

ArticleMedical microbiology and immunology2024

Exploration of compounds to inhibit the Panton-Valentine leukocidin of Staphylococcus aureus.

Tobias Grebe, Mithra Tatjana Sarkari, Angelika Cherkaoui, Frieder Schaumburg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical microbiology and immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. DisarmingPathogens (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tobias Grebe *Institute of Medical Microbiology, University of Münster, Domagkstraße 10, 48149, Münster, Germany. Tobias.Grebe@ukmuenster.de.
Mithra Tatjana Sarkari *Institute of Medical Microbiology, University of Münster, Domagkstraße 10, 48149, Münster, Germany.
Angelika CherkaouiInstitute of Medical Microbiology, University of Münster, Domagkstraße 10, 48149, Münster, Germany.
Frieder SchaumburgInstitute of Medical Microbiology, University of Münster, Domagkstraße 10, 48149, Münster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Panton-Valentine leukocidin (PVL) of Staphylococcus aureus is associated with necrotizing infections. After binding to complement 5a receptor (C5aR/CD88) and CD45 it causes cytolysis in polymorphonuclear neutrophils (PMNs) as well as inflammasome activation in monocytes. The objective of this study was to test if (ant)agonists of C5aR and CD45 can attenuate the effect of PVL on PMNs and monocytes. We tested the effect of various concentrations of six C5aR (ant)agonists (avacopan, BM213, DF2593A, JPE-1375, PMX205 and W-54011) and one CD45 antagonist (NQ301) to attenuate the cytotoxic effect of PVL on human PMNs and monocytes in vitro. Shifts in the half-maximal effective concentration (EC

Indexed as

Bacterial ToxinsExotoxinsLeukocidinsMonocytesNeutrophilsReceptor, Anaphylatoxin C5aStaphylococcus aureusAnti-Bacterial AgentsHumansInflammasomesInterleukin-1betaLeukocyte Common AntigensStaphylococcal InfectionsAnti-Bacterial AgentsBacterial ToxinsC5AR1 protein, humanExotoxinsInflammasomesInterleukin-1betaLeukocidinsLeukocyte Common AntigensPanton-Valentine leukocidinReceptor, Anaphylatoxin C5aAntagonistCD45CD88Complement 5a receptorPanton-Valentine leukocidinStaphylococcus aureus

Identifiers

PMID39297970
PMCPMC11413081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.